Regulus Therapeutics Presents New Data Strengthening Profile Of RG-101

(RTTNews) - Regulus Therapeutics Inc. (RGLS) presented new data strengthening the profile of RG-101, a wholly-owned, GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") for the treatment of HCV, during an oral late-breaking session at ILC 2015 in Vienna, Austria.

Extended follow-up results evaluating a single subcutaneous administration of either 2 mg/kg or 4 mg/kg of RG-101 as monotherapy in HCV patients with varied genotypes, liver fibrosis status and treatment history showed that 10/22 patients had HCV RNA levels below the limit of quantification ("BLOQ") at 12 weeks and 70 percent of those patients remained BLOQ at 20 weeks (7/10).

In addition, the positive results that were previously reported from the completed clinical study of RG-101 were reviewed during the oral late-breaker.

Regulus noted that it also made several poster presentations highlighting the pharmacokinetics and pharmacodynamics of RG-101 in healthy volunteers, the preclinical pharmacokinetics, pharmacodynamics, and toxicity of RG-101, and the efficacy of RG-101 in a preclinical model of HCV.